Tibet Aim Pharm (SZSE:002826) ROCE % : 17.17% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tibet Aim Pharm's annualized ROCE % for the quarter that ended in Mar. 2024 was 17.17%.

Tibet Aim Pharm ROCE % Historical Data

The historical data trend for Tibet Aim Pharm's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm ROCE % Chart

Tibet Aim Pharm Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

4.95

7.91

7.28

7.19

7.76

Tibet Aim Pharm Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															5.80	4.09	6.22	-3.24	17.17

Tibet Aim Pharm ROCE % Calculation

Tibet Aim Pharm's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	57.513	/	( ( (824.473 - 99.347)	+	(1018.205 - 261.914) )	/ 2 )
	=	57.513	/	( (725.126	+	756.291)	/ 2 )
	=	57.513	/	740.7085
	=	7.76 %

Tibet Aim Pharm's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	130.264	/	( ( (927.744 - 171.08)	+	(938.543 - 177.738) )	/ 2 )
	=	130.264	/	( ( 756.664	+	760.805 )	/ 2 )
	=	130.264	/	758.7345
	=	17.17 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Tibet Aim Pharm (SZSE:002826) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tibet Aim Pharm ROCE % Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tibet Aim Pharm (SZSE:002826) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000

Website

http://www.emyy.cn

Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.

Executives

Peng Hui	Director
Pang Guo Qiang	Directors, executives
Li Qian Jin	Securities Affairs Representative
Liu Hang	Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines